TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23733374

Group type: EXPERIMENTAL
Intervention: Be Fit Be Well program (2-year moderate intensity weight loss and blood pressure control intervention)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Be Fit Be Well program
Number of subjects: 365

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 365
Study: 21594216

Group type: EXPERIMENTAL
Intervention: 5 mm short implants
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10 mm long implants in augmented bone
Number of subjects: 30
Study: 19015346

Group type: EXPERIMENTAL
Intervention: Voriconazole pretreatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Itraconazole pretreatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 12
Study: 17210593

Group type: EXPERIMENTAL
Intervention: Epoetin alfa, maximum dosage >100 IU/kg/week during stabilization phase
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Epoetin dosage
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Unidentified patient characteristics
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Older age, higher BMI, anaemia, ACE inhibitor/ARB use, diabetes as primary cause of kidney disease
Number of subjects: 93
Study: 15473502

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Subjective Significance Questionnaire (SSQ)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Correlation between SSQ ratings and QLQ-C30 change scores
Number of subjects: 101
Study: 11036840

Group type: EXPERIMENTAL
Intervention: Intermittent cyclical etidronate therapy
Number of subjects: 5
Study: 9358616

Group type: EXPERIMENTAL
Intervention: Plasma rich in HIV antibodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard seronegative plasma
Number of subjects: 0
Study: 8252505

Group type: EXPERIMENTAL
Intervention: Goserelin plus flutamide
Number of subjects: 327
Study: 3888312

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSP) (n = 36)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Methotrexate (MTX) (n = 39)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 75
Study: 31558450

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (3 sessions per week)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Concentric exercise (5 sessions per week)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 50
Study: 28503827

Group type: EXPERIMENTAL
Intervention: Instrument-mounted wide-field white light clinical interferometry
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Instrument-mounted keratoscopy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hand-held keratoscopy
Number of subjects: 22
Study: 27352493

Group type: EXPERIMENTAL
Intervention: 'jin' theory acupuncture
Number of subjects: 95

Group type: COMPARATOR
Intervention: Regular acupuncture
Number of subjects: 95

Group type: COMPARATOR
Intervention: Medication (betahistine mesylate)
Number of subjects: 95
Study: 24561488

Group type: EXPERIMENTAL
Intervention: Once-daily voglibose
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Thrice-daily voglibose
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 151
Study: 22570073

Group type: EXPERIMENTAL
Intervention: Anterior approach (AA group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Classic approach (CA group)
Number of subjects: 66
Study: 20647773

Group type: EXPERIMENTAL
Intervention: Nimotuzumab (200 mg/dose, once a week for six weeks) with chemoradiation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 92
Study: 17548746

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 817
Study: 15770976

Group type: EXPERIMENTAL
Intervention: G‐SPECT in patients with GEs
Number of subjects: 22

Group type: COMPARATOR
Intervention: ECHO
Number of subjects: 22
Study: 11926695

Group type: EXPERIMENTAL
Intervention: Active ibuprofen 5% gel (Ibugel)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 81
Study: 9869212

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy plus surgery (R+S)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Surgery alone (S)
Number of subjects: 370
Study: 7543038

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg morphine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg nalbuphine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 29
Study: 2198909

Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Papaveretum-hyoscine
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 328192

Group type: EXPERIMENTAL
Intervention: Fructose (1.2 g.kg‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dextrose (1.2 g.kg‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30689608

Group type: EXPERIMENTAL
Intervention: Scheduled ripcord removal
Number of subjects: 81
Study: 28589334

Group type: EXPERIMENTAL
Intervention: Fixed bearing implant
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mobile bearing implant
Number of subjects: 40
Study: 25741971

Group type: EXPERIMENTAL
Intervention: Aluminum-adjuvanted PCV15
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nonadjuvanted PCV15
Number of subjects: 90

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both formulations of PCV15
Number of subjects: 90
Study: 23501476

Group type: EXPERIMENTAL
Intervention: Proximity to steel plant (0.9km)
Number of subjects: 61

Group type: COMPARATOR
Intervention: College site (4.5km)
Number of subjects: 61
Study: 21458143

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 98

Group type: COMPARATOR
Intervention: Free-hand injection without ultrasound guidance
Number of subjects: 98
Study: 19266265

Group type: EXPERIMENTAL
Intervention: Polyethyleneoxide (PEO) based heparin bonded extracorporeal circuits (ECC) + Continuous Leukocyte filtration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: uncoated ECC + leukofiltration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PEO based heparin bonded ECC without leukofiltration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 17484646

Group type: EXPERIMENTAL
Intervention: Minilaparoscopic cholecystectomy
Number of subjects: 712

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy
Number of subjects: 712
Study: 15329029

Group type: COMPARATOR
Intervention: Antibacterials
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Symptomatic treatment (antibacterials only if failed to improve after 7 days)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Empirical treatment (all patients initially treated with antibacterials)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Radiology-guided treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Treatment based on specific clinical criteria
Number of subjects: 58
Study: 10649155

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol plus 30 microg norgestimate
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol plus 90 microg norgestimate
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol plus 180 microg norgestimate
Number of subjects: 236

Group type: COMPARATOR
Intervention: 1 mg estradiol daily
Number of subjects: 236
Study: 9276354

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy plus BCNU for AAF/OL patients
Number of subjects: 133

Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy plus BCNU for AAF patients
Number of subjects: 133
Study: 8338086

Group type: EXPERIMENTAL
Intervention: Mesalamine 2 g daily
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Mesalamine 4 g daily
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 3566125

Group type: EXPERIMENTAL
Intervention: Auditory random noise preoperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: No auditory random noise
Number of subjects: 0
Study: 31479004

Group type: EXPERIMENTAL
Intervention: Morning exercise (amEX)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Evening exercise (pmEX)
Number of subjects: 40
Study: 29488628

Group type: EXPERIMENTAL
Intervention: Prenatal mindfulness training (MMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 28660498

Group type: EXPERIMENTAL
Intervention: Degarelix 2.8 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 80
Study: 26591622

Group type: EXPERIMENTAL
Intervention: 0.075% cetylpyridinium chloride (CPC) mouthwash
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Essential oils (EO) mouthwash
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fluoride-free, alcohol-free non-antibacterial mouthwash (NC)
Number of subjects: 120
Study: 22517190

Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) cigarettes
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (42 mg nicotine patches)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No cigarettes (control condition)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 56
Study: 21512399

Group type: EXPERIMENTAL
Intervention: CR2 (0.15 g·kg creatine during 2 d wk of RT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: CR3 (0.10 g·kg creatine during 3 d wk of RT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: PLA2 (placebo during 2 d wk of RT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: PLA3 (placebo during 3 d wk of RT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Men on creatine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Women on creatine
Number of subjects: 38
Study: 18283177

Group type: EXPERIMENTAL
Intervention: Audiovisual computerized presentations
Number of subjects: 101

Group type: COMPARATOR
Intervention: Written handouts
Number of subjects: 101
Study: 16493126

Group type: EXPERIMENTAL
Intervention: Wellness, Academics & You intervention
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 1013
Study: 12964450

Group type: EXPERIMENTAL
Intervention: Biofeedback assisted relaxation therapy (BFRT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 22
Study: 10329103

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 544

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 544
Study: 8712747

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 52

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (no antifungal agent)
Number of subjects: 52
Study: 1681560

Group type: EXPERIMENTAL
Intervention: BW234U (two different dosage ranges)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7036288

Group type: EXPERIMENTAL
Intervention: Intraarterial chemotherapy (DTIC 80 mg/m2 + 8 days prior to surgery)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Systemic chemotherapy (vinblastine 6 mg/m2, thiotepa 6 mg/m2, rufocromycine 60 microgram/m2, methotrexate 15 mg/m2 on day 1, procarbazine 30 mg/m2 for 7 days)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (chemotherapy identical to above + DTIC 300 mg/m2 for each course + BCG every 4 weeks + C. parvum every week)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 469
Study: 31808709

Group type: EXPERIMENTAL
Intervention: Open-label chamomile extract 1500 mg daily for 8 weeks
Number of subjects: 179
Study: 31801593

Group type: EXPERIMENTAL
Intervention: Fire needle therapy (group A1)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Moxibustion (group A2)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Calcipotriol ointment (group B)
Number of subjects: 160
Study: 27989514

Group type: EXPERIMENTAL
Intervention: 10mg hydrocortisone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 26564598

Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Evacetrapib combined with statins
Number of subjects: 377

Group type: COMPARATOR
Intervention: Statin monotherapy (rosuvastatin and simvastatin)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy and evacetrapib combined with statins
Number of subjects: 377
Study: 23844234

Group type: EXPERIMENTAL
Intervention: Vashe soak
Number of subjects: 47

Group type: COMPARATOR
Intervention: Soap and water wash
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Vashe wipes
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combined approach (soap and water wash followed by Vashe soak)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Soap and water bed baths
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Vashe bed baths
Number of subjects: 47
Study: 21742095

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 15603

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 15603
Study: 19212169

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastrojejunostomy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Billroth II reconstruction
Number of subjects: 75
Study: 16317063

Group type: EXPERIMENTAL
Intervention: Lispro insulin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular + NPH insulin (R+N)
Number of subjects: 10
Study: 15623591

Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg daily
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Thalidomide 400 mg daily
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Prednisone 50 mg on alternate days
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Overall (both thalidomide arms)
Number of subjects: 67
Study: 12194618

Group type: EXPERIMENTAL
Intervention: Independent practice of sitting balance as an addition to standard physiotherapy treatment based on the Bobath Approach for four weeks.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard physiotherapy treatment based on the Bobath Approach (control group).
Number of subjects: 28
Study: 11189402

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 116
Study: 7598286

Group type: EXPERIMENTAL
Intervention: 22-gauge Sprotte needle
Number of subjects: 234

Group type: COMPARATOR
Intervention: 25-gauge Sprotte needle
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 234
Study: 2088195

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg) + Clindamycin (600 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg) + Clindamycin (600 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg) + Clindamycin (600 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg) + Metronidazole (500 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg) + Metronidazole (500 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enoxacin (400 mg) + Metronidazole (400 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg) + Metronidazole (400 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg) + Ornidazole (500 mg)
Number of subjects: 20
Study: 520100

Group type: EXPERIMENTAL
Intervention: Aspirin (3600 mg/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Naproxen (750 mg/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibuprofen (1600 mg/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibuprofen (2400 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6356538

Group type: EXPERIMENTAL
Intervention: 4HR (isoniazid and rifampicin for 6 months)
Number of subjects: 851

Group type: COMPARATOR
Intervention: 4H (isoniazid alone for 6 months)
Number of subjects: 851

Group type: COMPARATOR
Intervention: 6H (isoniazid alone for 8 months)
Number of subjects: 851

Group type: COMPARATOR
Intervention: 4HZ (isoniazid and pyrazinamide for 6 months)
Number of subjects: 851

Group type: COMPARATOR
Intervention: 4H and 6H (isoniazid alone for 6 and 8 months)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: 4H or 6H (isoniazid alone for 6 and 8 months)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 851
Study: 31797716

Group type: EXPERIMENTAL
Intervention: NeuroSAFE technique
Number of subjects: 407

Group type: COMPARATOR
Intervention: Non-NeuroSAFE technique
Number of subjects: 407
Study: 30016316

Group type: EXPERIMENTAL
Intervention: Diagnosis-dependent ACT subsidies with free diagnostic testing
Number of subjects: 32404

Group type: COMPARATOR
Intervention: Standard package of health education, prevention, and referral services
Number of subjects: 32404
Study: 26879183

Group type: EXPERIMENTAL
Intervention: N-back training for healthy subjects
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: N-back training for ABI patients
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study: 24285618

Group type: EXPERIMENTAL
Intervention: Case management plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 22154397

Group type: EXPERIMENTAL
Intervention: Endurance training (E, n = 10)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Concurrent training (ER, n = 10)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (C, n = 12)
Number of subjects: 32
Study: 20885293

Group type: EXPERIMENTAL
Intervention: Sugammadex (0.22 mg/kg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Neostigmine (34 μg/kg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 99
Study: 17508624

Group type: EXPERIMENTAL
Intervention: Oral-B Pulsar (PUL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colgate 360 (COL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral-B Advantage Plus (AP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral-B CrossAction (CA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral-B CrossAction Power (CAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crest SpinBrush Pro (SBP)
Number of subjects: 0
Study: 16236039

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 8
Study: 12022585

Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10077031

Group type: EXPERIMENTAL
Intervention: OptiMARK (gadoversetamide injection) 0.1 mmol/kg
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: OptiMARK (gadoversetamide injection) 0.3 mmol/kg
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: OptiMARK (gadoversetamide injection) 0.5 mmol/kg
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 7548979

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 35
Study: 2209383

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control
Number of subjects: 172
Study: 7324833

Group type: EXPERIMENTAL
Intervention: buprenorphine (0.3 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: oxycodone (10 mg)
Number of subjects: 20
Study: 30777086

Group type: EXPERIMENTAL
Intervention: AZD7594 800 μg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: AZD7594 250 μg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: AZD7594 58 μg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All doses of AZD7594
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 29103052

Group type: EXPERIMENTAL
Intervention: Isradipine as a disease modifying agent for PD
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Recruitment strategies including multi-modal outreach and protocol modifications
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Referral sources for recruitment
Number of subjects: 336
Study: 25827292

Group type: EXPERIMENTAL
Intervention: Early enteral feeding (intraoperative nasojejunal tube placement and enteral feeding until adequate oral intake could be maintained)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Early enteral feeding
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard care (postoperative diet as tolerated)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 109
Study: 25798509

Group type: EXPERIMENTAL
Intervention: VIPP-SD (Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study: 21059817

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0, 10, 20, and 40 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 18793861

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 75
Study: 17530638

Group type: EXPERIMENTAL
Intervention: Bosentan (125 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no bosentan treatment)
Number of subjects: 24
Study: 15238592

Group type: EXPERIMENTAL
Intervention: Soy protein containing 99 mg of isoflavones (25.6 g daily for 12 months)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Total milk protein as a powder (placebo)
Number of subjects: 202